PYXS Stock Price
Pyxis Oncology, Inc.
PYXS stock price is $1.83 (+2.23% on the day), giving Pyxis Oncology, Inc. a market cap of $214.05M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
PYXS Stock Overview
- Price
- $1.83
- Previous close
- $1.79
- Open
- $1.79
- Market cap
- $214.05M
- P/E ratio
- -2.7
- 52-week range
- $1.03 - $4.15
- 1-year price target
- $8.44
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 37
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PYXS | $1.83 | +2.2% | 56.28K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |